

PROVIDER BULLETIN

PROVIDER INFORMATION



March 1, 2024

Medicare Part B Step Therapy Program Expansion to Include Rystiggo, and Vyvgart Hytrulo

As stewards of healthcare expenditures for our subscribers, Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) is charged with ensuring they receive the highest quality, evidence-based care. This is accomplished through development of medical policies and management of the policies to include the prior authorization (PA) process. The primary purpose of the PA process is to ensure that evidence-based care is provided to our subscribers, driving quality, safety, and affordability.

Reminder: As communicated in **Provider QuickPoint QP95-22** Minnesota Health Care Programs Operations Transition, and **Provider Bulletin P77-23** Minnesota Health Care Programs (MHCP) Operations Transitioning back to Blue Cross, **effective January 1, 2024, Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) transitioned Minnesota Health Care Programs (MHCP) Operations back to Blue Cross on January 1, 2024.** Blue Cross established a landing page on the website for all documents and information related to the transition: <https://www.bluecrossmn.com/providers/migration-minnesota-health-care-programs/mhpc>. As part of the MHCP transition, the Blue Cross Medical Policy II-247 for the Medicare Part B Step Therapy Program was expanded to include the Minnesota Senior Health Options (MSHO) lines of business.

Effective May 6, 2024, Blue Cross Medical policy II-247 for the Medicare Part B Step Therapy Program will be expanded to **add** a step therapy requirement to try Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) and Rystiggo (rozanolixizumab-noli), in addition to Vyvgart (efgartigimod alfa) and Ultomiris (ravulizumab) prior to Soliris (eculizumab) when deemed medically necessary to treat generalized myasthenia gravis, per policy guidelines. With the policy update, the Medicare Part B Step Therapy Program Drug List will be updated, accordingly.

The following medical policy change will be effective May 6, 2024:

Policy #	Policy Title/ Service	Preferred Products*	Non-Preferred Products*	Prior Authorization Requirement*	Line(s) of Business
II-247	Medicare Part B Step Therapy	Vyvgart Vyvgart Hytrulo Rystiggo Ultomiris	Soliris, for treatment of generalized myasthenia gravis	<p>Continued</p> <ul style="list-style-type: none"> Soliris: PA required using policy L33394 and II-247. Vyvgart: PA required using policy L33394. Ultomiris: PA required using policy II-229. <p>New</p> <ul style="list-style-type: none"> Vyvgart Hytrulo: PA required using policy L33394. Rystiggo: PA required using policy L33394 	Medicare Advantage, MSHO

*All existing PA approvals will be honored.

Products Impacted

The information in this bulletin applies **only** to subscribers who have coverage through Medicare Advantage and the Minnesota Senior Health Options (MSHO) lines of business.

Reminder Regarding Medical Policy Updates & Changes

Medical Policy changes are communicated in the Upcoming Medical Policy Notifications section of the Blue Cross Medical and Behavioral Health Policy website. The Upcoming Policies section lists new, revised, or inactivated policies approved by the Blue Cross Medical and Behavioral Health Policy Committee and are effective at minimum 45 days from the date they were posted. To access the website:

- Go to providers.bluecrossmn.com
- Under Medical Management, select “Upcoming medical policies.”

Questions?

For MSHO subscribers, please send an email to MHCPProviders@bluecrossmn.com. For Medicare Advantage subscribers, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.